The Oncogenomics Handbook

The Oncogenomics Handbook

von: William J. LaRochelle, Richard A. Shimkets

Humana Press, 2007

ISBN: 9781592598939 , 750 Seiten

Format: PDF

Kopierschutz: Wasserzeichen

Windows PC,Mac OSX für alle DRM-fähigen eReader Apple iPad, Android Tablet PC's

Preis: 213,99 EUR

  • Primary Care English
    Parkinson's Disease and Nonmotor Dysfunction
    Health Technology Assessments by the National Institute for Health and Clinical Excellence - A Qualitative Study
    Mit kollegialen Grüßen ... - Sprachdummheiten in der Medizin
    Yearbook of Intensive Care and Emergency Medicine 2007
    Intensive Care Medicine - Annual Update 2007
  • Multiple Sclerosis - Etiology, Diagnosis, and New Treatment Strategies
    How to Examine the Nervous System
    Die Therapie des Facio-Oralen Trakts - F.O.T.T. nach Kay Coombes
    Re-Engineering of the Damaged Brain and Spinal Cord - Evidence-Based Neurorehabilitation
    Diagnostic Criteria in Neurology
    Homocysteine Related Vitamins and Neuropsychiatric Disorders - Related Vitamins and Neuropsychiatric Disorders
 

Mehr zum Inhalt

The Oncogenomics Handbook


 

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.